IPCOR aims to improve prostate cancer outcomes and maximise patient quality of life
by feeding information back to hospitals and policymakers for quality improvement initiatives
About IPCOR
IPCOR is a clinical quality registry and biorepository recruiting patients referred for prostate biopsy through Rapid Access Prostate Clinics in public and private hospitals in Ireland. Following consent from participants, high-quality clinical data from medical charts and patient reported outcomes through questionnaires are captured and in some cases, biological samples for biobanking.
About IPCOR
Our Goals
Our main objective is to collect detailed clinical and quality of life data on participant's journey to get a diagnosis of and treatment for prostate cancer. Collecting and analysing this data will help inform future care delivery, knowledge of the disease and best use of health care innovations and resources.
About IPCOR
Research
In order to advance prostate cancer diagnosis and care, IPCOR will publish regular reports for participating hospital sites. Additionally, the data in our registry can be used for several type of research projects through collaborations with other teams, researchers and institutes. We hope these initiatives will boost patient experience and allow identification and resolution of gaps in the Irish healthcare system.
About IPCOR
What is IPCOR?
History and current activities
IPCOR was the first national prostate cancer outcomes registry in Ireland. Initiated in 2015, the first rendition collected clinical and quality of life data on 6816 men who were diagnosed with prostate cancer and treated in 16 hospitals around Ireland between 2016 and 2020. This first phase of the IPCOR registry was supported by the Irish Cancer Society, Movember and the National Cancer Registry of Ireland (NCRI). Data was collected under the NCRI consent waiver and later transferred to UCD.
Due to change in GDPR laws and changes in funding structure, the second phase of IPCOR launched in 2024 has improved consent-taking processes and uses advanced digital registry technology for prospective data collection and reporting. IPCOR now recruits all men referred for prostate biopsy, this allows inclusion of patients who test negative for prostate cancer but must be included to help improve the overall diagnostic process.
Following explicit consent of each participant at 5 major sites across Dublin and Galway, IPCOR is now able to analyse its extended clinical and patient-reported dataset in real-time, providing hospitals, consultants and patients novel insight into trends, gaps and outcomes from pooled data.
IPCOR 2 also requests and stores blood and urine samples from participants at the time of consent. All these samples are stored in a freezer until requested for research, such as building advanced non-invasive diagnostic techniques. Including men who test both negative and positive on biopsy allows for stronger research where risk factors and markers in the blood and urine can be compared across both groups.
Importance of a Clinical Quality Registry
Particularly in the Irish context
Clinical Quality Registry is a type of patient registry whose primary purpose is to monitor outcomes and report on quality of care within a specific health service. Quality indicators collected by clinical registries assess whether care is safe and effective and delivered in a timely and appropriate manner and report this back to institutions and/or clinicians.
Although Ireland has a national registry, detailed clinical variables i.e. information regarding specific test results, treatments done, complications, recurrence and patient's quality of life are not pooled and collected nationally. This is a particularly important initiative for prostate cancer patients because despite having a high survival rate, the treatments for this disease can often leave men with long term effects on their urinary, bowel and sexual function. The data collected by IPCOR now allows following patients through their diagnosis, treatment and long term follow up to really understand the support they require and how effective current practices are in managing this disease.
The IPCOR registry also recruits men who are referred for prostate biopsy but do not have prostate cancer. This is because the experiences of patients who test negative on biopsy are an essential component to understanding prostate-related patient pathways.
What's Important about Prostate Cancer?
Over 4,000 men are diagnosed with prostate cancer each year in Ireland, and one in eight men will be diagnosed with it during their lifetime
The prostate is a small gland that lies below your bladder. If there is an enlargement or abnormal growth in this gland it can press on the tube that carries urine and cause symptoms.
Even before symptoms develop, an elevated PSA (prostate-specific antigen) test can be a sign that your prostate needs to be investigated. Early detection can save lives and prevent adverse effects of treatment that may reduce quality of life of the affected individual.
Funding
IPCOR is a Movember funded project
It is managed and owned by the School of Medicine, University College Dublin (UCD). The Principal Investigator of IPCOR is Associate Clinical Professor Mr David Galvin, Consultant Urologist.